Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KIAA2012 is a protein encoded by the KIAA2012 gene in humans and is classified as an uncharacterized protein[1][4][6]. It is expressed at low levels across the body, with relatively higher expression in the ovary, lungs, and brain[1]. The protein is largely localized to the nucleus and contains a domain of unknown function (DUF 4670) as well as a highly conserved cGMP-dependent protein kinase binding domain[1]. KIAA2012 has predicted protein interactions with STAG2 and SMC1A, which are involved in cohesin complexes that regulate sister chromatid separation and cell division, suggesting a potential role in DNA manipulation or mitotic processes[1]. There are no common alternative names, approved molecular functions, or confirmed roles as a therapeutic target. Some genome-wide association studies have linked KIAA2012 gene variants to traits such as heel bone mineral density, educational attainment, lung function, and height, and its expression is reportedly altered in polycystic ovary syndrome, but no direct disease associations or therapeutic interventions are established[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Uncharacterized protein KIAA2012 (KIAA2012).